// App-Quantinova.ai

FRI-349 : Effects of Denosumab on Bone Mineral Density in Treatment-Naive Patients and Patients Previously Treated with Other Osteoporosis Therapies

Researchers

Presenter

  • Mohammed Almohaya

Principal Investigators

  • David L Kendler

Medical Centers

  • N/A

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoporosis

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Zoledronic acid

  • Teriparatide

  • Alendronate sodium

  • Risedronate sodium

  • LBS-101

  • Denosumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved